drugset / Trial / NCT03187405

Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage.

NCT03187405

Phase 3 Terminated 81 enrolled University Hospital, Caen
RandomizedParallel-groupSingle-blindTreatment

Summary

Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, with delayed cerebral ischemia (DCI) as a major complication. There are several evidences, both in preclinical and in clinical studies that intraventricular fibrinolysis (IVF) controls the phenomenon that are leading to DCI. Here, the investigators propose to conduct a phase III trial to provide a clear evaluation of the impact of IVF after aneurysmal SAH.

Timeline

Start
2018-02-21
Primary completion
2024-02-05
Completion
2025-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 1 mg Other